Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneMichael Gnant, Torsten O. Nielsen, Sean Ferree et al.|Annals of Oncology|2013Cited by 403
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 TrialGeorg Pfeiler, Michael Gnant, Robert Königsberg et al.|Journal of Clinical Oncology|2011Cited by 222
The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Torsten O. Nielsen, Margaretha Rudas et al.|Clinical Cancer Research|2014Cited by 219
Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 studyMichael Knauer, Michael Gnant, Christine Gruber et al.|Cancer Research|2015Cited by 21
Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial.Georg Pfeiler, Michael Gnant, Robert Königsberg et al.|Journal of Clinical Oncology|2014Cited by 7